drug_type
RELEVANT_DRUG
intervention_type
cellular therapy (CAR-NK)
drug_description
Gene-modified allogeneic natural killer cells expressing a chimeric antigen receptor targeting CD19 to mediate antigen-specific cytotoxicity against malignant B cells; administered in dose levels of 1×10^6, 5×10^6, or 2×10^7 cells/kg.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic natural killer cells genetically engineered to express a chimeric antigen receptor targeting CD19 on B cells. CAR binding to CD19 activates NK signaling to induce antigen-specific cytotoxicity (perforin/granzyme release and cytokine-mediated killing), leading to MHC-independent elimination of malignant CD19+ B cells.
drug_name
JD001 (allogeneic CD19-CAR-NK cells)
nct_id_drug_ref
NCT05739227